Alan Spatz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8626787/publications.pdf

Version: 2024-02-01

168 papers	11,983 citations	31976 53 h-index	28297 105 g-index
175 all docs	175 docs citations	175 times ranked	14159 citing authors

#	Article	IF	Citations
1	Spatially mapping the immune landscape of melanoma using imaging mass cytometry. Science Immunology, 2022, 7, eabi5072.	11.9	60
2	Molecular immunoâ€imaging improves tumor detection in head and neck cancer. FASEB Journal, 2022, 36, e22092.	0.5	0
3	A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. International Journal of Molecular Sciences, 2022, 23, 4443.	4.1	7
4	NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation. Oncogene, 2022, 41, 2984-2999.	5.9	3
5	The longitudinal impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: Interim analysis from a retrospective chart review.. Journal of Clinical Oncology, 2022, 40, e18737-e18737.	1.6	0
6	Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology, 2022, 40, 2627-2627.	1.6	0
7	Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. Analytical Chemistry, 2021, 93, 10816-10824.	6.5	7
8	Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. Cancers, 2021, 13, 3723.	3.7	5
9	Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. Lung Cancer, 2021, 160, 127-135.	2.0	16
10	A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110Î± in cell lines and tumor tissues. Analyst, The, 2021, 146, 6566-6575.	3.5	1
11	Importance of Adequate qPCR Controls in Infection Control. Diagnostics, 2021, 11, 2373.	2.6	1
12	Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma. Nature Cancer, 2020, 1, 635-652.	13.2	26
13	Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells. Proteomics - Clinical Applications, 2020, 14, 2000034.	1.6	5
14	Maximizing confidence in a negative result: Quantitative sample adequacy control. Journal of Infection and Public Health, 2020, 13, 991-993.	4.1	11
15	BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells. Cell Death Discovery, 2020, 6, 1.	4.7	59
16	Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition. Clinical Proteomics, 2020, 17, 5.	2.1	3
17	Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1328-1337.	1.1	19
18	Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring. ACS Pharmacology and Translational Science, 2020, 3, 1304-1309.	4.9	1

#	Article	IF	Citations
19	Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring. ACS Pharmacology and Translational Science, 2020, 3, 1304-1309.	4.9	6
20	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. Molecular Cancer Therapeutics, 2019, 18, 1628-1636.	4.1	18
21	Laboratory-developed test for detection of acute Clostridium difficile infections with the capacity for quantitative sample normalization. Diagnostic Microbiology and Infectious Disease, 2019, 95, 113-118.	1.8	4
22	A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Current Oncology, 2019, 26, 241-254.	2.2	34
23	The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. Lung Cancer, 2019, 132, 36-38.	2.0	19
24	Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. Cancers, 2019, 11, 1907.	3.7	12
25	Revitalising an academic pathology department: lessons learnt. Journal of Clinical Pathology, 2019, 72, 213-220.	2.0	4
26	Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer. Canadian Journal of Surgery, 2019, 62, 334-339.	1.2	6
27	Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Annals of Oncology, 2018, 29, 1417-1422.	1.2	92
28	Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC. Journal of Thoracic Oncology, 2018, 13, e161-e163.	1.1	9
29	How iMALDI can improve clinical diagnostics. Analyst, The, 2018, 143, 2197-2203.	3.5	20
30	Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy?. International Journal of Colorectal Disease, 2018, 33, 727-733.	2.2	3
31	Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Current Oncology, 2018, 25, 163-169.	2.2	28
32	Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC. Oncotarget, 2018, 9, 35472-35473.	1.8	3
33	Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).. Journal of Clinical Oncology, 2018, 36, 185-185.	1.6	2
34	Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, e15071-e15071.	1.6	0
35	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46
36	Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. , 2017, , .		2

#	Article	IF	Citations
37	Impact of the epigenetic modulator BORIS on sensitivity of melanoma cells to UV-induced DNA damage.. Journal of Clinical Oncology, 2017, 35, e21077-e21077.	1.6	0
38	Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. , 2017, , .		0
39	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 2016, 8, 369ra177.	12.4	33
40	One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. Journal of Clinical Oncology, 2015, 33, 9062-9062.	1.6	0
41	Molecular pathology of cutaneous melanoma. Melanoma Management, 2014, 1, 151-164.	0.5	4
42	Cutaneous melanoma. Lancet, The, 2014, 383, 816-827.	13.7	465
43	The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. Molecular Oncology, 2014, 8, 819-829.	4.6	149
44	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. Human Pathology, 2014, 45, 2006-2013.	2.0	5
45	From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting. Molecular Oncology, 2014, 8, 781-782.	4.6	3
46	A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. Journal of Clinical Oncology, 2014, 32, 9066-9066.	1.6	4
47	Molecular testing in Cutaneous Melanoma. , 2014, , 363-374.		1
48	Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care. BMC Dermatology, 2013, 13, 3.	2.1	33
49	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). Cancer Immunology, Immunotherapy, 2013, 62, 1223-1233.	4.2	5
50	Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Modern Pathology, 2013, 26, 1413-1424.	5.5	35
51	Biopsies: next-generation biospecimens for tailoring therapy. Nature Reviews Clinical Oncology, 2013, 10, 437-450.	27.6	110
52	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 2413-2420.	1.6	188
53	Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. British Journal of Cancer, 2013, 108, 1641-1647.	6.4	20
54	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. Journal of Clinical Oncology, 2013, 31, 3831-3837.	1.6	88

#	Article	IF	Citations
55	Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).. Journal of Clinical Oncology, 2013, 31, 9032-9032.	1.6	10
56	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinomaâ€"Now and in the Future. Current Oncology, 2012, 19, 24-32.	2.2	25
57	EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer. Current Oncology, 2012, 19, 67-74.	2.2	15
58	Skin Tumors Induced by Sorafenib; Paradoxic RASâ€"RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1. Clinical Cancer Research, 2012, 18, 263-272.	7.0	119
59	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. Journal of Clinical Oncology, 2012, 30, 3810-3818.	1.6	254
60	Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. Current Opinion in Oncology, 2012, 24, 137-140.	2.4	43
61	Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 2012, 48, 218-225.	2.8	182
62	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€“ Update 2012. European Journal of Cancer, 2012, 48, 2375-2390.	2.8	407
63	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 441-448.	2.8	49
64	EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?. British Journal of Cancer, 2012, 107, 1864-1868.	6.4	56
65	EORTC Melanoma Group achievements. European Journal of Cancer, Supplement, 2012, 10, 112-119.	2.2	0
66	Abstract 3389: Determining optimal conditions for collection and processing of metastatic liver biopsies collected for a multicenter, prospective study to identify biomarkers of clinical resistance to first-line therapy in metastatic colorectal cancer. , 2012, , .		1
67	Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience. , 2012, , .		0
68	Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors. Clinical Cancer Research, 2012, 18, B24-B24.	7.0	0
69	The dual role of the Xâ€linked FoxP3 gene in human cancers. Molecular Oncology, 2011, 5, 156-163.	4.6	21
70	Melanoma â€" The pieces of the puzzle finally start coming together!. Molecular Oncology, 2011, 5, 113-115.	4.6	2
71	Gene expression profiling of human angiotropic primary melanoma: Selection of 15 differentially expressed genes potentially involved in extravascular migratory metastasis. European Journal of Cancer, 2011, 47, 1267-1275.	2.8	31
72	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer, 2011, 47, 1476-1483.	2.8	189

#	Article	IF	Citations
73	Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies. Frontiers in Pharmacology, 2011, 2, 59.	3.5	19
74	Prognosis in Patients With Sentinel Nodeâ€“Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. Journal of Clinical Oncology, 2011, 29, 2206-2214.	1.6	195
75	Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival. , 2011, , .		0
76	Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodiesâ€”EORTC 18991. Journal of Clinical Oncology, 2010, 28, 2460-2466.	1.6	69
77	Reply to F. Janku et al. Journal of Clinical Oncology, 2010, 28, e17-e18.	1.6	9
78	The biology behind prognostic factors of cutaneous melanoma. Current Opinion in Oncology, 2010, 22, 163-168.	2.4	37
79	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2010, 46, 270-283.	2.8	284
80	Genetic and morphologic features for melanoma classification. Pigment Cell and Melanoma Research, 2010, 23, 763-770.	3.3	130
81	The biology of melanoma prognostic factors. Discovery Medicine, 2010, 10, 87-93.	0.5	10
82	Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology, 2009, 27, 2916-2923.	1.6	119
83	Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon. Journal of the National Cancer Institute, 2009, 101, 869-877.	6.3	72
84	Biomarkers in melanoma. Annals of Oncology, 2009, 20, vi8-vi13.	1.2	118
85	Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib. Journal of Clinical Oncology, 2009, 27, e59-e61.	1.6	152
86	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1713-1742.	6.4	159
87	Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. European Journal of Cancer, 2009, 45, 2736-2742.	2.8	56
88	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). European Journal of Cancer, 2009, 45, 3189-3197.	2.8	48
89	Dermatologic symptoms associated with the multikinase inhibitor sorafenib. Journal of the American Academy of Dermatology, 2009, 60, 299-305.	1.2	142
90	Selective expression of inhibitory Fcî³ receptor by metastatic melanoma impairs tumor susceptibility to IgGâ€dependent cellular response. International Journal of Cancer, 2008, 123, 2832-2839.	5.1	31

#	Article	IF	Citations
91	High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene, 2008, 27, 565-573.	5.9	228
92	Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. Oncogene, 2008, 27, 5223-5232.	5.9	22
93	Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. Oncogene, 2008, 27, 6601-6606.	5.9	12
94	The Janus face of dendritic cells in cancer. Oncogene, 2008, 27, 5920-5931.	5.9	80
95	The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma. Cytopathology, 2008, 19, 48-51.	0.7	11
96	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Molecular Oncology, 2008, 1, 425-430.	4.6	47
97	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, The, 2008, 372, 117-126.	13.7	620
98	Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor. Archives of Dermatology, 2008, 144, 886-92.	1.4	204
99	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. Clinical Cancer Research, 2007, 13, 3825-3830.	7.0	67
100	F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4â€‰mm. Melanoma Research, 2007, 17, 147-154.	1.2	51
101	Omics in melanoma â€“ what have we learnt and what is the potential impact for patient management?. European Journal of Cancer, Supplement, 2007, 5, 423-424.	2.2	0
102	BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Familial Cancer, 2007, 6, 453-461.	1.9	36
103	TuBaFrost 3: Regulatory and ethical issues on the exchange of residual tissue for research across Europe. European Journal of Cancer, 2006, 42, 2914-2923.	2.8	62
104	TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. European Journal of Cancer, 2006, 42, 2684-2691.	2.8	84
105	TuBaFrost 4: Access rules and incentives for a European tumour bank. European Journal of Cancer, 2006, 42, 2924-2929.	2.8	24
106	TuBaFrost 1: Uniting local Frozen Tumour Banks into a European Network: an overview. European Journal of Cancer, 2006, 42, 2678-2683.	2.8	39
107	TuBaFrost 5: Multifunctional central database application for a European tumor bank. European Journal of Cancer, 2006, 42, 3103-3109.	2.8	24
108	TuBaFrost 6: Virtual microscopy in virtual tumour banking. European Journal of Cancer, 2006, 42, 3110-3116.	2.8	30

#	Article	IF	Citations
109	Skin cancer incidence and survival in European children and adolescents (1978â€“1997). Report from the Automated Childhood Cancer Information System project. European Journal of Cancer, 2006, 42, 2170-2182.	2.8	49
110	Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging, 2006, 6, 24-29.	2.8	68
111	The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. Journal of Cutaneous Pathology, 2006, 33, 397-399.	1.3	4
112	Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Modern Pathology, 2006, 19, 1170-1180.	5.5	25
113	Factors to keep in mind when introducing virtual microscopy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 248-255.	2.8	66
114	Microcystic Adnexal Carcinoma: Report of Seven Cases Including One with Lung Metastasis. Dermatology, 2006, 212, 221-228.	2.1	58
115	Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis, 2006, 28, 724-731.	2.8	52
116	Dendritic cell derived-exosomes: biology and clinical implementations. Journal of Leukocyte Biology, 2006, 80, 471-478.	3.3	117
117	Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome. Journal of the National Cancer Institute, 2006, 98, 472-482.	6.3	457
118	Virtual Microscopy in Virtual Tumor Banking. Advances in Experimental Medicine and Biology, 2006, 587, 75-86.	1.6	12
119	The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. Journal of Cutaneous Pathology, 2005, 32, 268-273.	1.3	100
120	Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology, The, 2005, 6, 491-500.	10.7	527
121	Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. Journal of Medical Genetics, 2005, 43, 39-47.	3.2	50
122	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. Journal of Translational Medicine, 2005, 3, 10.	4.4	993
123	Influence of Genes, Nevi, and Sun Sensitivity on Melanoma Risk in a Family Sample Unselected by Family History and in Melanoma-Prone Families. Journal of the National Cancer Institute, 2004, 96, 785-795.	6.3	97
124	Soft Tissue Sarcomas. Journal of Clinical Oncology, 2004, 22, 2029-2031.	1.6	18
125	Is Systemic Disease in the Coelomic Epithelium Associated With BRCA1 Germline Mutations?. Journal of the National Cancer Institute, 2004, 96, 488-489.	6.3	1
126	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. Cancer Research, 2004, 64, 2192-2198.	0.9	94

#	Article	IF	Citations
127	X-Chromosome Genetics and Human Cancer. Nature Reviews Cancer, 2004, 4, 617-629.	28.4	162
128	Clinical and Histopathological Characterization of Cutaneous Melanomas in the Melanoblastoma-Bearing Libechov Minipig Model. Pigment Cell & Melanoma Research, 2004, 17, 24-35.	3.6	54
129	Comparative genomic hybridization analysis of hereditary swine cutaneous melanoma revealed loss of the swine 13q36-49 chromosomal region in the nodular melanoma subtype. International Journal of Cancer, 2004, 110, 232-238.	5.1	11
130	Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy Analysis of two cases, literature review and surgical implications. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 113, 251-254.	1.1	4
131	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cellâ€“dependent antitumor effects. Journal of Clinical Investigation, 2004, 114, 379-388.	8.2	248
132	CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes and Cancer, 2003, 38, 265-268.	2.8	31
133	The development of optimal pathological assessment of sentinel lymph nodes for melanoma. Journal of Pathology, 2003, 200, 314-319.	4.5	193
134	In vivo evolution of tumour cells after the generation of double-strand DNA breaks. British Journal of Cancer, 2003, 88, 1763-1771.	6.4	31
135	Tyrosine kinase inhibition and grey hair. Lancet, The, 2003, 361, 1056.	13.7	50
136	Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. European Journal of Cancer, 2003, 39, 1861-1865.	2.8	81
137	Human tissue research. European Journal of Cancer, 2003, 39, 2256-2263.	2.8	26
138	Reliability of the Histopathologic Diagnosis of Malignant Melanoma in Childhood. Archives of Dermatology, 2002, 138, 625.	1.4	83
139	An explosive course of squamous cell penile cancer in an AIDS patient. Annals of Oncology, 2002, 13, 475-479.	1.2	15
140	Pathologic staging of melanoma. Seminars in Oncology, 2002, 29, 370-381.	2.2	56
141	Human Melanoma Cell Migration Along Capillary-Like Structures In Vitro: A New Dynamic Model for Studying Extravascular Migratory Metastasis. Journal of Investigative Dermatology, 2002, 119, 703-704.	0.7	31
142	Identification of histological features associated with metastatic potential in thin (<1.0â€‰mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. Journal of Pathology, 2002, 197, 188-193.	4.5	55
143	Reproducibility of Histopathologic Diagnosis and Classification of Non-Melanocytic Skin Cancer: A Panel Exercise in the Framework of the Multicenter Southern European Study Helios. Tumori, 2001, 87, 95-100.	1.1	8
144	Surgical Management for Prophylactic Oophorectomy in Women with an Inherited Risk of Ovarian Cancer. Tumori, 2001, 87, 16-17.	1.1	1

#	Article	IF	Citations
145	Indium-III octreotide scintigraphy of Merkel cell carcinomas and their metastases. Annals of Oncology, 2001, 12, 807-811.	1.2	50
146	Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. Melanoma Research, 2001, 11, 117-122.	1.2	9
147	Microstaging in cutaneous melanoma. Journal of Pathology, 2001, 195, 525-529.	4.5	9
148	Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect. Genes Chromosomes and Cancer, 2001, 32, 195-202.	2.8	63
149	An experimental inter-expert telepathology network using static imaging. Journal of Clinical Pathology, 2001, 54, 752-757.	2.0	11
150	Spitz Tumors in Children. Archives of Dermatology, 1999, 135, 282-5.	1.4	197
151	The Spitz tumor 50 years later: Revisiting a landmark contribution and unresolved controversy. Journal of the American Academy of Dermatology, 1999, 40, 223-228.	1.2	58
152	Plexiform Spitz Nevus. American Journal of Dermatopathology, 1999, 21, 542.	0.6	51
153	Primary Yolk Sac Tumor of the Endometrium: A Case Report and Review of the Literature. Gynecologic Oncology, 1998, 70, 285-288.	1.4	43
154	Melanoma in Childhood: Review and Perspectives. Pediatric and Developmental Pathology, 1998, 1, 463-474.	1.0	15
155	Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (>â€ƒ5â€ƒmm). Histopathology, 1998, 33, 406-413.	2.9	38
156	Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]. Human Molecular Genetics, 1998, 7, 209-216.	2.9	345
157	Malignant Blue Nevus of the Vulva With Late Ovarian Metastasis. American Journal of Dermatopathology, 1998, 20, 408-412.	0.6	53
158	Value of high-frequency US for preoperative assessment of skin tumors.. Radiographics, 1997, 17, 1559-1565.	3.3	124
159	Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging.. Radiology, 1997, 204, 55-63.	7.3	123
160	Intratumoral oxygen tension in metastatic melanoma. Melanoma Research, 1997, 7, 400-406.	1.2	89
161	Eccrine porocarcinoma with intracerebral extension. European Radiology, 1997, 7, 573-575.	4.5	11
162	Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients.. Radiology, 1996, 200, 453-458.	7.3	62

#	Article	IF	Citations
163	Melanoma in childhood: An EORTC-MCG multicenter study on the clinico-pathological aspects. , 1996, 68, 317-324.		94
164	Intravaginal amputation of the uterine cervix with frozen section examination of the endocervical margin: a review of 414 consecutive patients. International Journal of Gynecological Cancer, 1996, 6, 452-455.	2.5	1
165	Melanoma arising de novo in childhood: experience of the Gustave-Roussy Institute. Melanoma Research, 1995, 5, 117-122.	1.2	12
166	Borderline and Malignant Serous Tumor Arising in Pelvic Lymph Nodes. International Journal of Gynecological Pathology, 1995, 14, 87-91.	1.4	49
167	Hepatocellular Carcinoma During Hormonotherapy for Prostatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 390-392.	1.3	19
168	Nucleolar Organizer Regions in Ovarian Tumors. International Journal of Gynecological Pathology, 1992, 11, 11-14.	1.4	11